NJ Bio
NJ Bio is a US-based CRO/CDMO specializing in antibody-drug conjugates, bioconjugation, and GMP clinical manufacturing, serving biopharmaceutical companies, early-stage biotechs, and ADC platform developers from discovery through Phase I/II clinical supply.
- Company typePrivate
- Founded2019
- HeadquartersPrinceton, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What NJ Bio does
NJ Bio, Inc. is a US-based contract research and manufacturing organization (CRO/CDMO) specializing in antibody-drug conjugates (ADCs), bioconjugation chemistry, and adjacent complex biotherapeutic modalities including oligonucleotides and mRNA. Founded in 2019 and headquartered in Princeton, New Jersey, the company operates GMP-compliant manufacturing facilities in Princeton and Bristol, Pennsylvania, plus a new oligonucleotide building block facility being built in Hyderabad, India. It functions as a wholly-owned subsidiary of Cohance Lifesciences (formerly Suven Pharma).
The company's core platform integrates bioconjugation, payload-linker synthesis, analytical and bioanalytical characterization (LC-MS and LBA), antibody production, and GMP clinical manufacturing within a single-site workflow spanning preclinical discovery through Phase I/II clinical supply. Proprietary technical assets include a linker-payload library of more than 2,000 combinations, a high-throughput screening platform evaluating 100+ monoclonal antibodies simultaneously, the AJICAP site-specific conjugation platform (integrated via partnership with Ajinomoto Bio-Pharma Services), validated payload classes (vedotin, emtansine, mafodotin, deruxtecan, govitecan), and OEB-5 high-containment capability for cytotoxic payloads. Translational research offerings include 200+ CDX and 1,000+ PDX oncology models.
NJ Bio generates revenue through fee-for-service CRO engagements (Express, Standard, and Custom Conjugation tiers), GMP CDMO manufacturing contracts with per-batch pricing, FTE (full-time equivalent) resource models, and integrated preclinical-to-clinical programs. Customers are primarily biopharmaceutical companies, early-stage biotechs, ADC platform companies, and oncology drug developers, engaged via "Request a Quote" custom pricing with no publicly disclosed rate cards. The go-to-market is enterprise direct sales with multi-year contracts.
NJ Bio firmographics
Firmographics- Name
- NJ Bio
- Legal name
- NJ Bio, Inc.
- Website
- https://njbio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NJ Bio is a US-based CRO/CDMO specializing in antibody-drug conjugates, bioconjugation, and GMP clinical manufacturing, serving biopharmaceutical companies, early-stage biotechs, and ADC platform developers from discovery through Phase I/II clinical supply.
- Ownership category
- akta.pro rank
NJ Bio industry classification
Industry- Product category
- Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
Keywords
Where NJ Bio is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
NJ Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Services (CRO): Fee-for-service research engagements covering ADC discovery, bioconjugation, analytical services, and translational research. Customers engage project-based with defined scopes, timelines, and deliverables. Service tiers include Express Conjugation (rapid screening), Standard Conjugation (preclinical), and Custom Conjugation (optimization).
- Contract Manufacturing Services (CDMO): GMP manufacturing services for ADC drug substance, payload-linkers, mRNA, and oligonucleotides supporting Phase I and Phase II clinical trials. Manufacturing includes process development, scale-up, and analytical characterization. Revenue generated through batch manufacturing contracts with per-batch pricing.
- Translational Research Services: In vivo and in vitro preclinical studies including xenograft models, PK/PD studies, and IND-enabling studies. Billed as standalone projects or integrated into larger drug development programs.
- FTE (Full-Time Equivalent) Models: Flexible resource allocation model where dedicated scientific team members are assigned to client projects, allowing scalable engagement based on project complexity and duration.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom Project-Based Pricing |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
NJ Bio product offering
Product offeringCore offering
NJ Bio is an integrated CRO/CDMO providing contract chemistry and biology services for antibody-drug conjugate (ADC), bioconjugate, oligonucleotide, and mRNA development. Its offerings span bioconjugation chemistry, payload-linker design and synthesis, high-throughput antibody screening, GMP clinical manufacturing for Phase I/II trials, bioanalytical characterization, and in vivo/in vitro translational research with oncology xenograft and PDX models. The company delivers these services to biopharmaceutical and biotechnology clients from co-located R&D and GMP facilities in Princeton, NJ and Bristol, PA.
Product overview
NJ Bio is an integrated chemistry service provider and Contract Development and Manufacturing Organization (CRO/CDMO) specializing in complex biotherapeutics. The company operates as a single-site integrated platform offering multiple interconnected services: ADC Services (the core offering) encompasses bioconjugation, payload-linker development, antibody production, and GMP manufacturing; Manufacturing and CDMO Services provides clinical manufacturing capabilities for ADCs, mRNA, oligonucleotides, and antibody-oligonucleotide conjugates; Bioconjugation Services enables chemical conjugation across proteins, peptides, and oligonucleotides; Payloads and Linkers supplies validated, custom, and novel linker-payload combinations; Translational Research Services offers preclinical in vivo/in vitro studies and IND-enabling support; Bioanalytical Services provides LC-MS and LBA-based analysis; Oligonucleotide Services handles custom synthesis and manufacturing; and mRNA Services supports IVT mRNA synthesis and modification. The portfolio is unified by shared chemistry expertise, integrated workflows, and co-located R&D and manufacturing facilities in Princeton, NJ and Bristol, PA.
Differentiator
Problem solved
Functional benefit
Products and services
- ADC Services Comprehensive contract research services for antibody-drug conjugate development spanning early-stage research through IND-enabling studies. Combines bioconjugation, payload-linker synthesis, antibody production, translational research, screening platforms, analytical characterization, and GMP manufacturing for Phase I and II clinical trials. Targeted at biopharmaceutical and biotech developers of ADC therapeutics.
- Manufacturing and CDMO Services GMP clinical manufacturing services for ADCs, complex bioconjugates, mRNA, oligonucleotides, antibody-oligonucleotide conjugates, and linker payloads. Includes purpose-built manufacturing suites for Phase 1 and Phase 2 clinical trial materials using single-use technology. Designed for biopharmaceutical clients requiring cGMP-compliant production for early-stage clinical trials.
- Bioconjugation Services Chemical conjugation services for coupling biomolecules (antibodies, proteins, peptides, oligonucleotides) with various chemical entities. Offers three engagement tiers: Express Conjugation for rapid ADC screening, Standard Conjugation for preclinical studies, and Custom Conjugation for clinical development optimization. Utilizes diverse chemistries including lysine- and cysteine-based modifications, affinity-based conjugation, oxime and biorthogonal chemistries, glycan remodeling, transglutaminase-based methods, non-natural amino acid incorporation, click chemistry, and enzyme-assisted conjugation.
- Payloads and Linkers Design, synthesis, and GMP manufacturing of chemical payload-linkers for ADCs. Includes clinically validated combinations (MC-VCP-MMAE vedotin, SMCC-DM1 emtansine, SPDB-DM4), custom payloads, and novel linker-payload development. Capabilities include handling OEB-5 materials (OEL <10 ng/m³) and scaling from milligrams to tens of kilograms. Targets ADC developers requiring cytotoxic payloads such as auristatins, maytansinoids, duocarmycins, PBD dimers, camptothecins, and IGNs.
- Translational Research Services Preclinical research services bridging discovery and clinical applications for oncology drug developers. Includes CDX models with over 200 authenticated human cancer cell lines, patient-derived xenograft (PDX) models with over 1,000 fully validated models spanning multiple disease indications, immuno-oncology studies, humanized mouse models, PK/PD studies, in vitro studies, IND-enabling research, and organoid/spheroid studies. Designed to support preclinical-to-clinical translation for oncology therapeutics.
- Bioanalytical Services Bioanalysis for ADCs and bioconjugates using Ligand Binding Assays (LBA/ELISA), Liquid Chromatography-Mass Spectrometry (LC-MS), and hybrid LBA-LC-MS platforms. Services include PK analysis, drug-to-antibody ratio (DAR) determination, free payload quantification, immunogenicity assessment, and metabolite profiling. Targeted at developers requiring sensitive quantification and biotransformation characterization of ADC and bioconjugate drug candidates.
- Oligonucleotide Services Custom oligonucleotide synthesis and manufacturing using Phosphoramidite solid-phase synthesis. Services include DNA/RNA synthesis, chemical modifications (phosphorothioate, 2' modifications, LNA, PNA), conjugation with biomolecules, and GMP manufacturing from research-grade to clinical-grade (Phase I/II). Targeted at developers of oligonucleotide-based therapeutics, including antisense oligos, siRNA, aptamers, and antibody-oligonucleotide conjugates.
- mRNA Services Custom mRNA synthesis and manufacturing via in vitro transcription (IVT). Services include linearized plasmid transcription, modified NTP synthesis (natural and unnatural), capping strategies (ARCA, mCAP), poly(A) tailing, purification, and analytical characterization. Available at scales from milligram to multigram (up to 20g). Targeted at mRNA therapeutic and vaccine developers requiring research-grade through clinical-grade material.
- High-Throughput Screening Bioconjugation High-throughput bioconjugation screening platform enabling rapid evaluation of over 100 monoclonal antibodies simultaneously to identify those best suited for ADC and bioconjugate development. Provides developability screening to support rational candidate selection. Targeted at ADC developers seeking efficient antibody screening prior to lead optimization.
- BioNMR Services BioNMR spectroscopy services for drug discovery and structural characterization. Supports structural elucidation of biologics, bioconjugates, and small molecules, providing analytical insight into therapeutic candidates during development. Targeted at biopharmaceutical researchers requiring structural and conformational characterization of drug candidates.
- Protein Degraders Services Chemistry services for targeted protein degraders including PROTAC and related molecular glue degrader modalities. Supports design, synthesis, and characterization of protein degrader conjugates and bifunctional molecules. Targeted at drug developers pursuing targeted protein degradation as a therapeutic modality.
- Medicinal Chemistry Services Medicinal chemistry services for small molecule drug discovery. Includes analog synthesis, structure-activity relationship (SAR) studies, lead optimization, and custom synthesis to support hit-to-lead and lead optimization campaigns. Targeted at pharmaceutical and biotech researchers pursuing small molecule therapeutics.
- Custom Synthesis of Small Molecules Custom synthesis of small molecules from milligram to multi-kilogram scale. Includes reference standards, building blocks, intermediates, and bespoke compounds for research and preclinical use. Targeted at pharmaceutical and biotech researchers requiring specialized chemical synthesis not available through standard catalogs.
- Synthesis of Nucleotides Custom synthesis of nucleotides including phosphoramidite building blocks, modified nucleotides, and oligonucleotide precursors. Supports oligonucleotide therapeutics manufacturing and ADC linker chemistry development. Targeted at developers of oligonucleotide-based drugs and ADC linker chemistries requiring specialized nucleotide inputs.
- Analytical Services Analytical services for ADCs, small molecules, and large molecules. Includes method development, method validation, release testing, and stability studies supporting discovery through clinical manufacturing. Targeted at biopharmaceutical developers requiring cGMP-compliant analytical characterization of drug substance and drug product.
- Antibody Production Antibody production services including monoclonal antibody expression, purification, and characterization to support ADC and bioconjugate development programs. Targeted at ADC and bioconjugate developers requiring antibody materials for screening, conjugation, and preclinical evaluation.
- Cell-Based Functional Assays Cell-based functional assay services including cytotoxicity assays, potency assays, and mechanism-of-action studies. Supports biotherapeutic characterization and ADC efficacy evaluation in vitro. Targeted at biotherapeutic developers requiring functional characterization of antibody and ADC candidates.
- Combined Payload-Linker Manufacturing Services Integrated payload-linker manufacturing combining payload synthesis and linker conjugation under a single service engagement. Streamlines the supply chain for ADC developers by delivering ready-to-use payload-linker intermediates. Targeted at ADC developers seeking simplified vendor management for payload-linker procurement.
Quantifiable outcome
- Rapid ADC screening with high-throughput evaluation of 100+ monoclonal antibodies simultaneously
- +2 more outcomes
Companies that use NJ Bio
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
NJ Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
NJ Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Ajinomoto Bio-Pharma ServicescoreResearch collaboration to integrate AJICAP site-specific conjugation platform into NJ Bio's ADC discovery and development workflows. Partnership aims to enhance NJ Bio's capabilities in site-specific conjugation, supporting development of targeted therapeutics with emphasis on reducing development risks and improving project outcomes through conjugation precision.
- L2P Research LabscoreAsset purchase and full integration of L2P Research Labs' services to expand NJ Bio's translational research offerings. Acquisition enhances capabilities in preclinical and early-phase clinical research, particularly in oncology, supporting more seamless progression from proof-of-concept to clinic.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
NJ Bio competitors and assessment
Company assessmentDirect peers
- WuXi XDC: WuXi XDC is the leading pure-play ADC CDMO, providing end-to-end antibody, payload-linker and bioconjugation services from discovery through GMP manufacturing. It is the closest direct competitor to NJ Bio in target customers, service scope and ADC specialization.
- Novasep (Pharma Solutions): Novasep offers CDMO services including highly potent API manufacturing and bioconjugation for ADC clients. Its specialization in cytotoxic payloads and complex chemistry makes it a direct comparator to NJ Bio.
- Piramal Pharma Solutions: Piramal operates an ADC CDMO business with payload-linker development and GMP manufacturing capacity. It targets the same biopharma and biotech customers with comparable ADC-centric service offerings.
- Sterling Pharma Solutions: Sterling Pharma Solutions is a CDMO specializing in API development and high-potency manufacturing with growing bioconjugation services. Its focus on complex small molecules and HPAPIs overlaps directly with NJ Bio's payload-linker work.
- Carbogen Amcis: Carbogen Amcis specializes in highly potent API and payload-linker synthesis with GMP manufacturing, including OEB-5 containment for cytotoxic payloads. Its high-potency focus makes it a direct comparator to NJ Bio's payload-linker capability.
Emerging players
- Ajinomoto Bio-Pharma Services: Ajinomoto Bio-Pharma Services offers cGMP biologics manufacturing and the AJICAP site-specific conjugation platform, with which NJ Bio has a formal partnership. It is both a potential competitor and partner in the ADC technology space.
- BioDuro: BioDuro is a CRO/CDMO offering drug discovery, development and manufacturing services including ADC-related chemistry. It serves similar biotech customers but with broader small-molecule emphasis rather than ADC specialization.
Broad incumbents
- AGC Biologics: AGC Biologics provides biologics CDMO services including bioconjugation and antibody-related manufacturing. It serves biopharma clients at clinical and commercial scale, making it a broad incumbent competitor in the bioconjugate space.
- Catalent (now part of Novo Holdings): Catalent offers bioconjugation and ADC development services across its global network of GMP facilities. It is a broad incumbent CDMO with overlap on ADC/bioconjugate work but competes from a much larger small-molecule and biologics platform.
- Lonza (Bioconjugates): Lonza is a global CDMO incumbent with a dedicated bioconjugates business unit offering ADC process development and GMP manufacturing. It competes with NJ Bio in clinical-stage ADC manufacturing but as part of a much broader services portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
NJ Bio social profiles
Digital presenceNJ Bio compliance and trust
Trust signalCompliance1 record
NJ Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
NJ Bio leadership team
Management profileNumber of profiles
Profiles1 record
NJ Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NJ Bio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NJ Bio
What does NJ Bio do?
NJ Bio is an integrated CRO/CDMO providing contract chemistry and biology services for antibody-drug conjugate (ADC), bioconjugate, oligonucleotide, and mRNA development. Its offerings span bioconjugation chemistry, payload-linker design and synthesis, high-throughput antibody screening, GMP clinical manufacturing for Phase I/II trials, bioanalytical characterization, and in vivo/in vitro translational research with oncology xenograft and PDX models. The company delivers these services to biopharmaceutical and biotechnology clients from co-located R&D and GMP facilities in Princeton, NJ and Bristol, PA.
Is NJ Bio a public or private company?
NJ Bio is a private company. It is classified as corporate owned and is currently operating.
When was NJ Bio founded?
NJ Bio was founded in 2019. It employs 101 to 250 people.
Where is NJ Bio based?
NJ Bio is headquartered in Princeton, United States, in the North America region.
How does NJ Bio make money?
Four revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Manufacturing Services (CDMO), translational Research Services and FTE (Full-Time Equivalent) Models.
Who are NJ Bio's main competitors?
Direct peers on record are WuXi XDC, Novasep (Pharma Solutions), Piramal Pharma Solutions, Sterling Pharma Solutions and Carbogen Amcis. Emerging players are Ajinomoto Bio-Pharma Services and BioDuro. Broad incumbents are AGC Biologics, Catalent (now part of Novo Holdings) and Lonza (Bioconjugates).
Does NJ Bio have an API?
No public API is recorded for NJ Bio.
What industry is NJ Bio in?
NJ Bio's product category is Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeutics. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.